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Background: There is evidence that tumour–stroma interactions have a major role in the neoplastic progression of pancreatic
ductal adenocarcinoma (PDAC). Tumour budding is thought to reflect the process of epithelial–mesenchymal transition (EMT);
however, the relationship between tumour buds and EMT remains unclear. Here we characterize the tumour-budding- and
stromal cells in PDAC at protein and mRNA levels concerning factors involved in EMT.
Methods:mRNA in situ hybridisation and immunostaining for E-cadherin, b-catenin, SNAIL1, ZEB1, ZEB2, N-cadherin and TWIST1
were assessed in the main tumour, tumour buds and tumour stroma on multipunch tissue microarrays from 120 well-characterised
PDACs and associated with the clinicopathological features, including peritumoural (PTB) and intratumoural (ITB) budding.
Results: Tumour-budding cells showed increased levels of ZEB1 (Po0.0001) and ZEB2 (P¼ 0.0119) and reduced E-cadherin and
b-catenin (Po0.0001, each) compared with the main tumour. Loss of membranous b-catenin in the main tumour (P¼ 0.0009) and
tumour buds (P¼ 0.0053), without nuclear translocation, as well as increased SNAIL1 in tumour and stromal cells (P¼ 0.0002, each)
correlated with high PTB. ZEB1 overexpression in the main tumour-budding and stromal cells was associated with high ITB
(P¼ 0.0084; 0.0250 and 0.0029, respectively) and high PTB (P¼ 0.0005; 0.0392 and 0.0007, respectively). ZEB2 overexpression in
stromal cells correlated with higher pT stage (P¼ 0.03), lymphatic invasion (P¼ 0.0172) and lymph node metastasis (P¼ 0.0152).
Conclusions: In the tumour microenvironment of phenotypically aggressive PDAC, tumour-budding cells express EMT
hallmarks at protein and mRNA levels underlining their EMT-type character and are surrounded by stromal cells expressing
high levels of the E-cadherin repressors ZEB1, ZEB2 and SNAIL1, this being strongly associated with the tumour-budding
phenotype. Moreover, our findings suggest the existence of subtypes of stromal cells in PDAC with phenotypical and functional
heterogeneity.
In the era of personalised medicine, pancreatic ductal adenocarci-
noma (PDAC) remains a highly lethal malignancy, characterised
by a striking desmoplastic reaction. Its lethal nature is attributed to
the rapid dissemination of cancer cells to the lymphatic system and
distant organs (Hidalgo, 2010; Fernandez-del-Castillo et al, 2013).
Moreover, PDAC escapes early detection and resists treatment
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(Stathis and Moore, 2010; Fernandez-del-Castillo et al, 2013).
To date, however, the management of PDAC remains suboptimal,
as available conventional and targeted treatments against the
cancer cells have given only limited results. Therefore, the
identification of additional prognostic/predictive biomarkers under
consideration of the stromal component, which would enable
better patient stratification and eventually provide a guide towards
a more successful and individualised therapy appears mandatory
(Tuveson and Hingorani, 2005; Hidalgo, 2010; Fernandez-del-
Castillo et al, 2013).
Detachment of cancer cells from the main tumour body and
invasion of the surrounding stroma, taking place at the cancer–
host interface, is an important first step for the development of
distant metastasis (Gabbert et al, 1992). Tumour buds, observed at
the invasive front of many gastrointestinal cancers, refer to the
presence of isolated single cells or small cell clusters (up to five
cells) detached from the main tumour and thought to represent a
very aggressive subpopulation of cancer cells (Prall, 2007). Budding
cells seem indeed able to degrade the peritumoral connective tissue
to evade host’s response and finally to infiltrate the lymphatic and
blood vessels leading to local and distant metastasis (Lugli et al,
2012). Tumour budding has been consistently associated with
adverse clinicopathological characteristics and poor outcome, in
most studies independent of other strong prognostic factors such
as pathological stage (Hase et al, 1993; Tanaka et al, 2003;
Nakamura et al, 2008; Wang et al, 2009). We could recently show
that tumour budding is a strong and independent prognostic factor
in PDAC (Karamitopoulou et al, 2013a).
Tumour budding is thought to morphologically reflect the
process of epithelial–mesenchymal transition (EMT), which is
defined in vitro in cell culture models and allows neoplastic
epithelial cells to acquire a more mesenchymal phenotype thus
increasing their capacity for migration and invasion and helping
them become resistant to apoptotic signals (Guarino et al, 2007;
Mani et al, 2008; Kalluri, 2009; Thiery et al, 2009; Krantz et al,
2012). However, there is controversy regarding the relationship
between budding cells and EMT process, as there is currently no
direct evidence that human cancer cells can undergo EMT (Celest
et al, 2013). To date, it has not been attempted to further
characterize tumour buds; especially no RNA-based studies have
been performed.
We hypothesise that tumour-budding cells are EMT-type cells
and that the tumour–stroma crosstalk at the tumour micro-
environment may influence the EMT-type tumour-budding
phenotype in PDAC. Aim of the present study is therefore to
characterise the tumour-budding- and stromal cells in pancreatic
cancer regarding expression of EMT-related factors at a protein
and mRNA level by using mRNA in situ hybridisation (ISH),
which has the advantage of preserving the tissue morphology and
to correlate the findings with clinicopathologic factors including
intratumoral and peritumoral budding (ITB and PTB, respec-
tively). The identification of tumour-budding-promoting profiles
could significantly contribute to our understanding of the events
that influence progression to invasion, metastasis and drug
resistance in PDAC (Arumugam et al, 2009). As most PDAC
patients present with advanced disease, resistant to adjuvant
therapy, this could also have an implication in future treatment
developments.
MATERIALS AND METHODS
Patients. Overall 120 nonconsecutive PDAC patients with com-
plete treatment and follow-up information, treated at the second
Department of Surgery, University of Athens Medical School, were
included into the study. Paraffin blocks from all patients have been
selected from the archives of the Department of Pathology,
University of Athens Medical School, Greece. All selected cases had
at least 1.2-cm tumour tissue thickness in at least two paraffin
blocks in order to be included into the study. Patients were treated
between 2001 and 2011. All histomorphological data were reviewed
from the corresponding H&E-stained slides, whereas clinical data
were obtained from corresponding patient records. Clinicopatho-
logical data included patient age, gender, tumour location, pT, pN,
pM, lymphatic invasion, vascular invasion, tumour grade,
histological subtype, disease-free interval and overall survival.
Information on post-operative therapy is available for all patients.
Ethical consent has been obtained for this project from the
Scientific and Ethical Committee of the Universities of Athens and
Bern. Patient characteristics are summarised in Supplementary
Table 1. The study design can be visualised in Supplementary
Figure 1.
Tissue microarray (TMA) construction. Two TMAs were
constructed including punches from primary tumours. In order
to exclude bias due to possible tumour heterogeneity, each patient
had multiple tumour punches (two from the tumour centre and
two from the invasive front, including tumour buds) taken from
formalin-fixed, paraffin-embedded blocks using a tissue cylinder
with a diameter of 1mm, which were subsequently transferred into
one recipient paraffin block (3 2.5 cm) using a semiautomated
tissue arrayer.
Assessment of tumour budding. Tumour budding was defined as
detached single cells or clusters of less than five cells. Cases were
evaluated for tumour budding using a 10-in-10 approach
(Karamitopoulou et al, 2013b). Briefly, whole-tissue sections of
each case underwent immunohistochemistry for AE1/AE3 (pan-
cytokeratin) staining. The 10 densest hotspots of tumour budding
were evaluated at high magnification ( 40, 0.55mm2) and
counted. The average number of buds per case was obtained.
Although tumour budding is described to occur mostly at the
invasive front of cancers (peritumoral budding), in our PDAC
series we frequently observed the presence of buds within the main
tumour body as well (ITB). Using a receiver operating character-
istic (ROC) curve approach, a cutoff score of 10 buds on average
was identified as most discriminatory for survival. Cases with an
average of 410 buds were classified as ‘high’ budders; those with
p10 buds were assigned as ‘low’ budders (Supplementary
Figure 2).
Immunohistochemical analysis. Whole-tissue sections of forma-
lin-fixed, paraffin-embedded PDAC tissue from all 120 patients
have been stained immunohistochemically for b-catenin (1 : 500;
Abcam, Cambridge, UK), E-Cadherin (1 : 200; Dako, Glostrup,
Denmark), ZEB1 (1 : 200; Sigma-Aldrich, St Louis, CA, USA),
ZEB2 (1 : 400; Sigma-Aldrich), SNAIL1 (Clone EC3, 1.10; antibody
developed and characterised previously by Francı´ et al, 2006; Mani
et al, 2008) N-cadherin (1 : 300; Abcam), TWIST1 (1 : 75; Abcam),
a-smooth muscle actin (a-SMA, 1 : 100 000; Sigma-Aldrich).
Antigen retrieval was performed with Tris-HCl, pH 9 for 30min
at 951. Antibody testing and staining protocols have been
established and staining was performed by an automated Leica
Bond RX System with the Bond Polymer Refine Kit (with DAB as
chromogen) and Bond Polymer Refine Red Detection Kit for the
double staining (Leica Biosystems, Newcastle, UK). Immunohis-
tochemistry was evaluated by estimating visually the percentage of
positive cells per TMA punch in 5% intervals (0, 5,y, 100%). In
the case of multiple tumour punches per localisation, the average
protein expression was calculated across all punches from the
same localisation. Evaluation was performed blinded to clinical
endpoints.
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mRNA-ISH. mRNA ISH for the EMT genes was performed on
TMA sections using the RNAscopeFFPE Assay kit (Advanced Cell
Diagnostics, Hayward, CA, USA), on an automated platform
(Discovery Ultra, Ventana Medical System – Roche, Tucson, AZ,
USA). The following probes from RNA ScopeVR (Advanced Cell
Diagnostics) were used: VS Probe-Hs-CDH1, NM_004360.3, probe
region: 263-1255; VS Probe-Hs-CTNNB1, NM_0010998210.1,
probe region: 285-2315; VS Probe-Hs-SNAI1, NM_005985.3,
probe region: 17-1233; VS Probe-Hs-ZEB1, NM_001174096.1, probe
region: 548-2253; VS Probe-Hs-ZEB2, NM_001171653.1, probe
region: 587-1446.
As negative control, DapB (dihydrodipicolinate reductase gene)
mRNA expression of Bacillus subtilis, and as ‘positive control’,
PPIB (peptidylprolyl isomerase B) were used. A punch core needed
to show control positivity to be assessed with the specific RNA
probes.
mRNA was found at the cytoplasm of cells and scored as
follows: 0: completely negative; 1þ : rare dots recognised by high
magnification ( 40); 2þ : easily recognised dots at high
magnification (40þ ); 3þ : easily recognised dots at moderate
magnification ( 20); 4: easily recognised dots at low magnifica-
tion ( 10).
Statistical analysis. In order to determine a valid cutoff score for
mRNA and/or protein expression (low/high), ROC curve analysis
was performed, using the end point of tumour budding.
Association of mRNA and/or protein expression with categorical
clinicopathological features was performed using the w2-test and
the Fisher’s Exact tests; for continuous variables such as age and
tumour size, the nonparametric Wilcoxon’s Rank Sum test was
used. For matched analyses, the Wilcoxon’s Signed Rank test for
pairs was used. Univariate survival time analysis was performed
using the log-rank test and differences plotted using Kaplan–Meier
curves. P-valueso0.05 were considered statistically significant.
Correction for multiple hypothesis testing was not carried out
(Perneger, 1998). Analyses were performed using SAS (V9.2; The
SAS Institute, Cary, NC, USA).
RESULTS
Protein expression of EMT markers. Results are summarised in
Table 1. Normal pancreatic tissue and precursor lesions (PanINs)
showed a strong membranous staining for E-cadherin and
b-catenin. The low-budding cases also showed preservation of
the membranous b-catenin and E-cadherin and markedly reduced
nuclear ZEB1 and ZEB2. On the contrary, high-budding cases
showed a reduced membranous expression of both E-cadherin and
b-catenin with almost complete loss of protein expression in the
tumour buds. No nuclear translocation of b-catenin was found.
In addition, an increased nuclear ZEB1 and ZEB2 expression was
observed in tumours with high budding, especially in the budding
cells. Tumour buds frequently expressed cytoplasmic N-cadherin.
Nuclear SNAIL1 and TWIST1 expression was seen mostly in the
stromal and rarely in some tumour-budding cells. Examples of
protein expression of the EMT markers including expression in
normal pancreatic tissue, precursor lesions (PanINs) and PDAC
specimens are shown in Supplementary Figure 3 (E-cadherin) and
Supplementary Figure 4 (b-catenin).
Correlation of mRNA levels with EMT marker expression.
SNAIL1 mRNA correlated positively with ZEB1 mRNA (r¼ 0.462)
and ZEB2 mRNA (r¼ 0.414) as well as with ZEB1 protein
expression in the main tumour (cc 0.631) and buds (r¼ 0.690).
ZEB1 mRNA showed a negative association with CDH1
(E-cadherin) mRNA (r¼  0.42) and CTNNB1 (b-catenin)
mRNA (r¼  0.326), whereas it correlated positively with SNAIL1
mRNA (r¼ 0.462), ZEB2 mRNA (r¼ 0.455) as well as with ZEB1
protein expression in the main tumour (r¼ 0.371), buds
(r¼ 0.333) and stromal cells (r¼ 0.371).
ZEB2 mRNA showed a similar negative correlation with CDH1
mRNA (r¼  0.414) and CTNNB1 mRNA (r¼  0.28) and a
positive correlation with ZEB1 mRNA (r¼ 0.455) and SNAIL1
mRNA (r¼ 0.414). Moreover, it showed surprisingly a negative
correlation with ZEB2 protein expression in stromal cells
(r¼  0.25). CDH1 mRNA showed a strong positive correlation
with CTNNB1 mRNA (r¼ 0.641). The results are summarised in
Supplementary Table 2. Examples of mRNA-ISH staining of EMT
markers including normal pancreatic tissue and PDAC specimens
are shown in Supplementary Figure 3 (CDH1) and Supplementary
Figure 4; CTNNB1). Positive and negative controls for mRNA-ISH
are shown in Supplementary Figure 5.
Differences between the main tumour body and tumour
buds. Tumour buds showed a significant loss of membranous
E-cadherin and b-catenin protein expression when compared with
the main tumour body (Po0.0001). On the contrary, nuclear ZEB1
and ZEB2 protein expression levels were significantly increased in
the tumour buds compared with the main tumour body
(Po0.0001 and 0.0119, respectively, Table 2).
Correlation with a tumour-budding phenotype. A high-tumour-
budding phenotype, especially regarding PTB, was characterised by
loss of membranous b-catenin in the main tumour and the tumour
buds (P¼ 0.0009 and 0.0053, respectively), increased nuclear
expression of SNAIL1 in tumour and stromal cells (P¼ 0.0003
and 0.0002, respectively) and increased nuclear expression of ZEB1
in tumour-, budding- and stromal cells (P¼ 0.0005, 0.0392 and
0.0007, respectively). Nuclear ZEB2 expression in the buds was also
correlated with high PTB (P¼ 0.0035). In addition, loss of
membranous E-cadherin in the tumour showed a trend towards
high PTB (P¼ 0.0727; Table 1).
High ITB was characterised by overexpression of nuclear ZEB1
in the main tumour (P¼ 0.0084), in the tumour buds (P¼ 0.0250)
and in the stromal cells (P¼ 0.0029; Table 1). Characteristic
Table 1. Correlation of average protein expression of EMT
markers with ITB and PTB budding
ITB PTB
Markers Low High P-value Low High P-value
E-cadherin tumour 54 51.04 0.4476 54 51.4 0.4277
E-cadherin buds 22.4 18.32 0.1507 20.56 18.6 0.3293
b-catenin tumour 36.3 39.29 0.6233 29.26 45.26 0.0009
b-catenin buds 8.75 10.04 0.8283 4.94 12.96 0.0053
SNAIL tumour 0.26 0.04 0.2761 0.25 0.06 0.0002
SNAIL stroma 4.56 5.66 0.8173 3.06 6.81 0.0002
SNAIL1 buds 1 1.34 0.2883 1 1.41 0.1795
ZEB1 tumour 20.66 30.3 0.0084 19.42 33.6 0.0005
ZEB1 buds 39.33 52.7 0.0250 40.95 53.8 0.0392
ZEB1 stroma 41.12 51.8 0.0029 40.73 53.5 0.0007
ZEB2 tumour 38.47 41.4 0.5097 47 36.6 0.1566
ZEB2 buds 44.74 43.3 0.8464 55.5 36.4 0.0035
ZEB2 stroma 1.9 1.6 0.7454 2.22 1.55 0.6603
N-cadherin tumour 0.04 0.07 0.8004 0.05 0.07 0.5855
N-cadherin buds 0.16 0.19 0.9081 0.22 0.16 0.4976
TWIST1 tumour 0.097 0.1 0.9631 0.14 0.07 0.2261
TWIST1 stroma 0.32 0.33 0.9885 0.31 0.31 0.9497
TWIST1 buds 0.06 0.03 0.3543 0.08 0 0.0737
Abbreviations: EMT¼ epithelial–mesenchymal transition; ITB¼ intratumoural budding;
PTB¼peritumoural budding. Statistically significant P values are in bold.
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examples of protein- and mRNA-ISH staining of the EMT markers
in the tumour buds are depicted in Figure 1.
Correlation with clinicopathological features. High levels of
SNAIL1 mRNA (P¼ 0.0142) and ZEB1 mRNA (P¼ 0.0243), as
well as TWIST protein expression in the tumour buds
(P¼ 0.0023), were associated with the presence of distant
metastasis (pM1, Supplementary Table 3). ZEB2 protein expres-
sion in the tumour stroma was associated with higher pT stage
(P¼ 0.03), lymphatic invasion (P¼ 0.0172) and the presence of
lymph node metastasis (P¼ 0.0152). ZEB1 overexpression in the
main tumour was associated with positive resection margins
(R1, P¼ 0.0043) and N-cadherin overexpression with higher the
T-stage (P¼ 0.0194; Supplementary Table 3).
ZEB1 and ZEB2 expression in stromal cells. Increased levels of
ZEB1 protein and ZEB1 mRNA were observed not only in the
main tumour and in the tumour buds but in the tumour
stroma as well. Moreover, ZEB1 expression in the stromal cells
was associated with a high-tumour-budding phenotype,
whereas ZEB2 positivity was mostly seen in cases with the higher
T-stage, lymphatic invasion and presence of lymph node
metastases (Supplementary Table 3). Stromal cells surrounding
PanIN and stromal cells in non-neoplasic pancreatic tissue
remained negative for ZEB1 and/or ZEB2. Examples of
mRNA-ISH and ZEB1- and ZEB2-protein expression by the
stromal cells, including double staining for ZEB1/a-SMA
and ZEB2/a-SMA to better demonstrate the nature of
ZEB1- and/or ZEB2-positive stromal cells as cancer-associated
fibroblasts, are shown in Figure 2. The schematic representation
of the most important findings is shown in Figure 3. Expression
overlaps between main tumour, tumour buds and stroma are
highlighted in Figure 4.
Table 2. Differences on average protein expression between
the main tumour and tumour buds
Main tumour Buds P-value (matched)
E-cadherin 52.9 19.7 o0.0001
b-catenin 38 9.4 o0.0001
ZEB1 25.8 46.3 o0.0001
ZEB2 30 43.7 0.0119
50 m 50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
50 m
Figure 1. Examples of IHC and mRNA-ISH staining for EMT markers in the tumour buds. (A) Reduced membranous E-cadherin protein expression
in the tumour buds,  600. (B) Reduced signals of CDH1 mRNA in the tumour buds,  600. (C) Tumour buds with reduced b-catenin protein
expression, 600. (D) Reduced signals of CTNNB1 mRNA in the tumour buds, 600. (E) Nuclear expression of the ZEB1 protein in the
tumour buds,  600. (F) Many signals of Zeb1 mRNA in the tumour buds,  600. (G) Nuclear expression of the ZEB2 protein in the tumour
buds,  600. (H) Many signals of Zeb2 mRNA in the tumour buds,  600. (I) Strong nuclear expression of the SNAIL1 protein in the tumour buds,
 600. (J) Many signals of Snail1 mRNA in the tumour buds, 600. (K) Increased N-cadherin protein expression in the budding cells, 600.
(L) Increased TWIST protein expression in the budding cells,  600.
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DISCUSSION
In the present study we characterize the tumour-budding- and
stromal cells in pancreatic cancer and show that budding cells
express EMT hallmarks at protein and mRNA levels. Moreover, we
find that stromal cells in the immediate environment of tumour
buds express the E-cadherin repressors SNAIL1 and ZEB1, this
expression being strongly associated with the EMT-type tumour-
budding phenotype, whereas the expression of ZEB2 by the
stromal cells significantly correlates to the presence of lymph node
metastasis.
Although tumour budding has been likened to EMT, the
relationship between budding cells and EMT-type cells remains
currently unclear. Budding cells examined mainly in gastrointest-
inal cancers, such as colorectal cancer, have been shown by
immunohistochemistry to lack membranous E-cadherin, to express
nuclear b-catenin indicating activation of WNT signalling and to
overexpress fibronectin and laminin 5 gamma 2, suggesting an
EMT phenotype (Kirchner and Brabletz, 2000; Schmalhofer, et al,
2009). In a recently published study Bronsert et al (2014)
performed a quantitative three-dimensional (3D) assessment of
tumour budding at the cancer–host interface in human pancreatic,
colorectal, lung and breast adenocarcinoma showing that budding
tumour cells display a shift towards spindle-like as well as rounded
morphology, associated with decreased E-Cadherin-staining inten-
sity and increased nuclear ZEB1 expression. In agreement with this
we show that in pancreatic cancer tumour-budding cells not only
have an immunohistochemical EMT signature, but this is also
reflected by the mRNA levels of the examined EMT factors within
the cell cytoplasm. Our findings underline the EMT-type character
of budding cells showing that the morphological phenotype of
tumour budding is genetically very similar to the EMT process.
Especially the combination ‘SNAIL1þ /ZEB1þ /b-catenin ’
correlated strongly with high budding and can be regarded as
‘budding-promoting profile’ in PDAC.
In contrast to other cancers such as colorectal cancer where
budding cells have been described to express nuclear b-catenin
(Kirchner and Brabletz, 2000), this phenotype was not seen in any
of our PDAC cases. In the present study tumour-budding cells
displayed loss of membranous b-catenin, paralleled by reduced
CTNNB1 mRNA levels, but without cytoplasmic accumulation or
nuclear translocation of the protein. This may indicate that the
activation of the canonical Wnt pathway is not a prerequisite for
the process of EMT-type tumour budding in PDAC. Activation of
the Wnt/b-catenin pathway in pancreatic cancer has been mainly
shown in tissue culture studies (Zhang et al, 2013; Arensman et al,
2014), whereas in the literature there are some contradicting results
50 m50 m
50 m50 m
50 m 50 m
Figure 2. Examples of IHC and mRNA-ISH staining for ZEB1 and ZEB2
in the stromal cells. (A) Strong nuclear expression of the ZEB1 protein
in the tumour stroma, 400. (B) Many signals of Zeb1 mRNA in the
stromal cells,  400. (C) Strong nuclear expression of the ZEB2 protein
in the tumour stroma, 400. (D) Many signals of Zeb2 mRNA in the
stromal cells,  400. (E) Double staining showing nuclear expression of
the ZEB1 protein (in red) in a-SMA-positive stromal cells (brown),
 400. (F) Double staining demonstating nuclear expression of the
ZEB2 protein (in red) in a-SMA-positive cells (brown) in the tumour
stroma, 400.
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Figure 3. Schematic representation of the most important findings of the present study.
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regarding activation of the canonical vs non-canonical Wnt
pathway (Weekes and Winn, 2011; Zhang et al, 2013). More-
over, mutations in APC, AXIN or CTNNB1 that hyperactivate
Wnt/b-catenin signalling are rare in PDAC (White et al, 2012).
Our results support the view that in the PDAC canonical Wnt
pathway is probably not involved at this advanced stage of cancer
cell invasion and migration. Rather the activation of other
pathways, known to be involved in pancreatic cancer progression
like the TGFb pathway (Ellenrieder et al, 2001; Gore et al 2014)
may induce the EMT-type tumour-budding phenotype in
pancreatic cancer. Indeed, according to previous studies TGFb-
driven EMT is sufficient to generate migrating cancer stem cells by
directly linking the acquisition of cellular motility with the
maintenance of tumour-initiating (stemness) capacity (Cufı´ et al,
2010). However, a low-level activation of the canonical Wnt
pathway that escapes detection by immunohistochemistry cannot
be excluded.
There is strong evidence that stromal cells by interacting with
tumour cells are involved in pancreatic cancer progression (Apte
et al, 2013). Our findings suggest that this may involve the
regulation of the EMT-type tumour-budding phenotype and the
metastatic spread in PDAC. However, the mechanism of this
interaction remains unclear. One hypothesis could be that some
stromal cells represent complete mesenchymally transformed
tumour cells. Indeed, stromal cells have been found to exhibit
similar genetic alterations with tumour cells in chromosome-
unstable colorectal cancers (Celesti et al, 2013). Another hypothesis
could be that there is a special phenotype of cancer-associated
fibroblasts associated with and supporting EMT-type tumour
budding through cellular crosstalk in the tumour microenviron-
ment of PDAC. Expression of the transcription factor ZEB1 has
been reported to occur in the stromal compartment of breast
carcinomas, supposing to represent two populations of cells: EMT-
transformed neoplastic cells and stromal fibroblastic cells under-
going activation of ZEB1 due to growth factors produced by the
tumour (Soini et al, 2011). Furthermore, Schulte et al (2012)
recently reported that distinct subpopulations of fibroblasts are to
various extents associated with EMT and tumour progression in
urothelial bladder cancer. In accordance to this, our results suggest
that there are distinct phenotypes of stromal cells exhibiting
different clinicopathological associations. Indeed, the SNAIL1þ /
ZEB1þ /ZEB2 phenotype of the stromal cells was associated
with high EMT-type tumour budding, whereas the SNAIL1 /
ZEB1 /ZEB2þ phenotype was mostly seen in cases with higher
T-stage, lymphatic invasion and presence of lymph node
metastases. Interestingly, these phenotypes were restricted to
PDAC tissues and were not found in the normal pancreatic tissue
or in the stroma surrounding PanINs.
This study should be understood in the context of its
limitations. Although TMAs provide an efficient and cost-effective
tool for testing a comprehensive panel of potential biomarkers on a
large number of tumour specimens, the TMA technique could raise
concerns related to the sampling of large, heterogeneous tumours.
The effect of tumour heterogeneity was minimised by sampling at
least four punches from each tumour and by especially including
punches from the advancing tumour front in order to contain the
tumour buds. Our study may further be limited by the fact that all
cases come from a single centre. Nonetheless, our study benefits
from complete clinicopathological data and the adherence to the
REMARK guidelines (McShane et al, 2005).
This study has also several strong points. To our knowledge, this
may be the first study to characterize tumour buds at the mRNA
level by using mRNA-ISH that has the advantage of preservation of
the tissue and cellular morphology. Moreover, we carry out
thorough evaluation of mRNA and corresponding protein
expression of several EMT markers in the main tumour, the
tumour buds and the tumour stroma.
In conclusion, our results show that in the tumour microenvir-
onment of PDAC tumour-budding cells not only express hallmarks
of EMT at the protein and mRNA level, but are also surrounded by
stromal cells expressing transcription factors that are strongly
associated with an EMT-type tumour-budding phenotype. More-
over, our findings suggest that EMT-type tumour budding in
pancreatic cancer, in contrast to other cancers, occurs without
detectable nuclear b-catenin suggesting no or low-level activation
of the canonical Wnt pathway. Furthermore, our findings support
the existence of phenotypically distinct subtypes of cancer-
associated fibroblasts in PDAC with different clinicopathological
associations.
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